

FOI Request for the Number of Patients Treated

1. Please complete the number of patients treated with Synagis (palivizumab) in the grid below. Please note that the total number of patients (A to E) in each column must add to total patients in the last row in the corresponding column.

Patients / babies treated with Synagis in the last three years	Total number patients treated with Synagis (Palivizumab) April 2018 to March 2019	Total number patients treated with Synagis (Palivizumab) April 2017 to March 2018	Total number patients treated with Synagis (Palivizumab) April 2016 to March 2017
A. Total number of patients with BPD / CLD diagnosis	12	13	11
B. Total number of patients with CHD diagnosis	*	*	8
C. Total number of <29wga (without BPD/CHD diagnosis)	0	0	0
D. Total number of multiple births immunised (without BPD/CHD diagnosis)	0	0	0
E. Other patients (please specify: _____)	6 <ul style="list-style-type: none"> • NNPY Support • Consultant request • Consultant request*1 • Consultant request*2 • 2nd season Chronic lung • 2nd season chronic lung home 02 	* <ul style="list-style-type: none"> • NNPY Support • 36wks, Compromised airway • 2nd season mitochondrial myopathy • 2nd season cardiac surgery, trisomy 	6 <ul style="list-style-type: none"> • Second season, 25 weeks, home 02 • Overnight CPAP • HIE, Seizures, NGT fed*3 • 39wks, Diaphragmatic Hernia*4 • 38wks, Diaphragmatic Hernia* • Nemaline Rodmyopathy*6
Total number of patients ¹	**	**	25

BPD: bronchopulmonary dysplasia; CLD: Chronic Lung Disease; CHD: congenital heart disease

***1 Home 02 consultant request *2 Twin of *1 *3 consultant request *4 Consultant request *5 Consultant request *6 Consultant request**

2. Please advise which OPCS codes are used within your Trust to code respiratory syncytial virus (RSV) prophylaxis treatment.

Code Description	Used within Trust to indicate patient received RSV prophylaxis treatment? Yes/No
X86.5 Respiratory syncytial virus prevention drugs band 1	Yes
X44.2 Intramuscular injection of vaccine	Yes
Other (if not listed above, please specify code(s)):	

3. If your Trust does not provide RSV prophylaxis treatment and you refer your patients to another Trust, please state to which Trust(s) patients are referred. **Not Applicable.**

¹ Total patients treated with Synagis in each of the last 3 years

We are required to pass on to our client details of any Adverse events and Product Complaints pertaining to their products that are mentioned during this research. If this happens, we will need to collect details and report the event, even if it has already been reported by you directly to the company or the regulatory authorities using the MHRA's 'Yellow Card' system. You will be asked whether you consent to us passing your details to the client company's drug safety department for their follow up, but you may choose to remain anonymous. This will have no impact on the confidentiality and anonymity associated with the research itself.

Adverse events should be reported.
Reporting forms and information can be found at <https://yellowcard.mhra.gov.uk/>
Adverse events should also be reported to AbbVie on UK_PVVendor@abbvie.com